|
Multidrug-resistant organism
|
Number of patients treated for MDRO
|
Prevalence of MDRO (%, number of patients treated for MDRO on number of patients receiving antimicrobials for therapeutic use (CAI and HAI))
|
|---|
|
MRSA
|
29
|
2.7
|
|
MRCoNS
|
6
|
0.6
|
|
VRE
|
10
|
0.9
|
|
ESBL
|
20
|
1.8
|
|
3-ceph
|
11
|
1.0
|
|
CRE
|
0
| |
|
ESBL-NF
|
2
|
0.2
|
|
CR-NF
|
2
|
0.2
|
|
Other MDRO
|
19
|
1.7
|
- Abbreviations: 3-ceph 3rd generation cephalosporin resistant Enterobacteriaceae (non-ESBL or ESBL status unknown), CAI community-acquired infection, CRE carbapenem-resistant Enterobacteriaceae, CR-NF carbapenem-resistant non-fermenter Gram-negative bacilli, ESBL bacteria producing extended-spectrum beta-lactamases, ESBL-NF ESBL-producing non-fermenter Gram-negative bacilli, HAI healthcare-associated infection, MDRO multi-drug resistant organism, MRCoNS methicillin-resistant coagulase negative staphylococci, MRSA methicillin-resistant Staphylococcus aureus, VRE Vancomycin-resistant enterococci
